Oculus Innovative Sciences’ CEO and Founder Named One of Pharmaceutical Executive’s 2008 “Emerging Pharma Leaders”

PETALUMA, Calif.–(EMWNews)–Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced that its CEO

and founder, Hoji Alimi, has been named one of the 2008 Pharmaceutical

Executive “Emerging Pharma Leaders.”

Selected by members of the magazine’s

editorial advisory board and a panel of judges, Mr. Alimi demonstrates “the

passion, vision, and dedication that leadership requires—and

that the pharmaceutical industry needs to reach its full potential as a

global healthcare leader.” The “Emerging

Pharma Leaders” feature appeared in the June

2008 issue of the publication.

“I’m honored to

have been chosen among this distinguished group of leaders from the

pharmaceutical and biotech industries,” said

Mr. Alimi. “But this recognition would never

have been possible if it wasn’t for the

notable team of Oculus employees worldwide that I have had the

opportunity to lead. They have been willing to do whatever is required

to get the job done–from the advancement of our U.S. clinical program

and commercialization of our multiple Microcyn®

applications to taking our story to the market. I couldn’t

be prouder of a team.”

Hoji Alimi has served as CEO, president and founder of Oculus Innovative

Sciences since 1999. At the beginning of his career, Mr. Alimi served as

the corporate microbiologist for Arterial Vascular Engineering, Inc

(AVE). Mr. Alimi received a B.A. in biology from Sonoma State University.

Mr. Alimi’s 2008 Pharmaceutical Executive

emerging pharma leader profile may be found at the link below:

http://pharmexec.findpharma.com/pharmexec/ArticleStandard/Article/

detail/524391 (Due to its length, this URL may need to be

copied/pasted into your Internet browser’s

address field. Remove the extra space if one exists.)

About the Emerging Leadership Awards

The ELAs were based on a nomination-led process. Following several

call-for-entries promotions, Pharmaceutical Executive accepted

nominations until April 1, 2008. Following that date, nominations were

placed into categories across job functions. Pharmaceutical Executive

then worked with its editorial advisory board and others to judge the

various entrants based on a set of key criteria. Executives that

received the highest ranking in their respective categories in the

judging process were profiled in this feature.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops,

manufactures and markets a family of products based upon the Microcyn®

Technology platform, which is intended to help prevent and treat

infections in chronic and acute wounds. The Microcyn Technology platform

is a biocompatible, shelf-stable solution containing active oxychlorine

compounds that is currently commercialized outside the United States

(Europe, India and Mexico) for the treatment of infected wounds. The

solutions derived from the Microcyn Technology platform have

demonstrated, in a variety of research and investigational studies, the

ability to treat a wide range of pathogens, including

antibiotic-resistant strains of bacteria (including MRSA and VRE),

viruses, fungi and spores. A recently completed U.S. Phase II clinical

trial of Microcyn Technology met the primary endpoints of safety and

efficacy for the treatment of mildly infected diabetic foot ulcers.

In addition to the company’s existing and

under-development therapeutic products, Oculus also develops,

manufactures and markets a number of 510k devices and products for both

professional and consumer. Oculus’ principal

operations are in Petaluma, California, and it conducts operations in

Europe, Latin America and Japan. More information can be found at the

company’s web site, www.oculusis.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions